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Abstract: Autism spectrum disorder (ASD) is a common neurodevelopmental disorder 
characterized by pervasive difficulties since early childhood across reciprocal social communication 
and restricted, repetitive interests and behaviors. Although early ASD research focused primarily 
on children, there is increasing recognition that ASD is a lifelong neurodevelopmental disorder. 
However, although health and education services for children with ASD are relatively well estab-
lished, service provision for adults with ASD is in its infancy. There is a lack of health services 
research for adults with ASD, including identification of comorbid health difficulties, rigorous 
treatment trials (pharmacological and psychological), development of new pharmacotherapies, 
investigation of transition and aging across the lifespan, and consideration of sex differences and 
the views of people with ASD. This article reviews available evidence regarding the etiology, 
legislation, diagnosis, management, and service provision for adults with ASD and considers what 
is needed to support adults with ASD as they age. We conclude that health services research for 
adults with ASD is urgently warranted. In particular, research is required to better understand 
the needs of adults with ASD, including health, aging, service development, transition, treatment 
options across the lifespan, sex, and the views of people with ASD. Additionally, the outcomes of 
recent international legislative efforts to raise awareness of ASD and service provision for adults 
with ASD are to be determined. Future research is required to identify high-quality, evidence-based, 
and cost-effective models of care. Furthermore, future health services research is also required 
at the beginning and end of adulthood, including improved transition from youth to adult health 
care and increased understanding of aging and health in older adults with ASD.
Keywords: autism, adults, diagnosis, management, service development
Introduction
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by 
pervasive difficulties since early childhood across reciprocal social communication and 
restricted, repetitive interests and behaviors.1,2 Although early research in ASD focused 
primarily on children, there is increasing recognition that ASD is a lifelong neurode-
velopmental disorder that has a potentially detrimental impact on adult functioning.3
While health and education services for children with ASD are relatively well estab-
lished, service provision for adults with ASD is in its infancy. There is a lack of health 
services research for adults with ASD,4–8 including identification of comorbid health 
difficulties, rigorous treatment trials (pharmacological and psychological), development 
of new pharmacotherapies,9 transition and aging across the lifespan,10 sex differences, 
life skills, consideration of the views of people with ASD,7 and cost and efficiency of 
services.8 Here, we review recent developments in understanding the etiology, legisla-
tion, diagnosis, management, and service provision for people with ASD across the 
adult lifespan and consider what is needed to support adults with ASD as they age.
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Etiology
ASD – a public health concern
ASD was initially described as a rare disorder of childhood.11,12 
However, the estimated prevalence rate of ASD has changed 
significantly over the past 40 years, perhaps in part because 
of increasing awareness of ASD and changes in diagnostic 
criteria and classification systems.13 In 1966, the prevalence 
of autism was estimated to be just four cases per 10,000 
people.14 However, ASD is now recognized as a common, 
lifelong15 neurodevelopmental disorder that affects ~1% of 
both the child16 and adult17 population.
The estimated prevalence of ASD is increasing, making 
it more common than several other better recognized condi-
tions, such as heart disease and diabetes.9 Despite this, 80% 
of adults with ASD report marked difficulties in accessing 
diagnostic services.18 Furthermore, ASD is associated with 
significant financial and emotional costs to the individual, 
their families, and society across health, education, and 
social systems.19 The estimated lifetime cost of supporting a 
person with ASD is substantial: $2.4 million in the USA and 
£1.5 million in the UK.19 These costs include accommoda-
tion, individual productivity loss (employment/education), 
and health, all of which may be contributed to by unman-
aged mental health difficulties in adulthood. Additionally, 
preliminary evidence suggests that unmet needs arising from 
comorbid mental health problems in young adults with ASD 
contribute to caregiver burden.20
The unmet health needs of people with ASD, lack of 
adult services,6 lack of treatment,21 and increasing prevalence 
rates13 contribute to the escalating disease burden on people 
with ASD as they age, their families, and society.9 Hence, 
there is an urgent need for improved mental health care for 
people with ASD across the lifespan that facilitates rapid, 
direct translation of scientific findings to clinical care.9,22 This 
should include better understanding of the neurobiological 
causes of ASD and associated comorbid and cognitive dif-
ficulties for children and adults with ASD, development 
of clinical treatment trials, the provision of high-quality, 
evidence-based, and age-appropriate treatments,10 and con-
sideration of the views of people with ASD in research and 
services development.7
Despite media concerns about an epidemic of autism,23 
the trend of increased prevalence rates is not thought to relate 
to an increased incidence of ASD. Instead, there is good evi-
dence that increased prevalence rates of ASD are associated 
with increased awareness of ASD, a resultant relative increase 
in service availability, and changes in diagnostic criteria.24–26 
Accordingly, autism, and the associated spiraling increase in 
demand for clinical service provision for people with ASD, 
has been identified by the United Nations and the World 
Health Organization as a public health concern.27,28
Despite this, to date there are no validated treatments 
for the core symptoms of ASD,29,30 and only a limited range 
of evidence-based treatments exist for associated mental 
health problems21,31 of adults with ASD. As such, there is an 
urgent need for improved understanding of the neurobiol-
ogy and health of people with ASD across the lifespan, for 
consideration of the views of people with ASD and their 
families regarding service development and research,32 and 
for the development of targeted, individualized, age-specific 
treatments.9
ASD – etiology of a highly heritable 
neurodevelopmental disorder
Asperger11 and Kanner’s12 seminal descriptions of children 
with autism and their families also detailed parental behav-
iors, and thus provided the first descriptions of possible 
familial and genetic traits of ASD. However, despite early 
evidence of a possible genetic contribution to ASD, this was 
not further investigated for some decades. Instead, psycho-
dynamic theories became influential in the 1960s, and it was 
suggested that poor parenting and social deprivation caused 
autism, as evidenced by the damning but previously widely 
used term refrigerator mothers.33
This psychodynamic view of autism was challenged by 
increasing evidence of genetic associations with autism. For 
example, Folstein and Rutter’s34 groundbreaking twin study 
found not only greater evidence for autism in monozygotic 
than dizygotic twins but also that identical twins with autism 
did not have identical symptoms of autism. This provided 
crucial first evidence of what is now recognized as a deter-
mining feature of ASD: heterogeneity.
Genetic investigation of autism started to proliferate 
in the 1980s with the recognition of the association of rare 
syndromes and chromosomal disorders with ASD.35 ASD 
is now considered to be a highly heritable, heterogeneous, 
neurodevelopmental disorder, with an estimated heritabil-
ity of ~90%.36 However, both genetic and environmental 
factors are thought to contribute to the development of 
ASD. A recent twin study37 estimated that genetic variables 
contribute 35%–40% toward the risk of developing an ASD 
and that the remaining 60% is contributed to by prenatal, 
perinatal, and postnatal environmental factors.
Environmental risk factors associated with ASD include 
prenatal and perinatal complications,38,39 exposure to viruses 
(particularly rubella), birth and neonatal complications,40,41 
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such as hypoxia,42 and increased paternal age. Studies in 
Israel and Sweden have reported that children fathered by 
men older than 40–50 years are two to five times more likely 
to develop ASD than children fathered by men 29 years or 
younger.43,44 It has been suggested that the increased risk of 
ASD with older fathers may be related to epigenetic changes 
associated with aging, including germ-line changes and 
exposure to toxins.43
The risk of developing autism can now be calculated for 
family members; siblings of people with idiopathic autism 
have a 2%–8% increased risk of having autism themselves,45 (a 
25-fold increase above the general population),46 while siblings 
of people with ASD and a dominant single gene disorder (such 
as tuberous sclerosis) have a recurrence risk of 50%.47 The 
genetics of autism are complex, partly due to its significant 
heterogeneity. Overall, however, there is now overwhelming 
evidence that ASD is a complex, neurobiologically deter-
mined, heterogeneous neurodevelopmental disorder.37,46,47
Sex differences
ASD is diagnosed more commonly in males than females, 
with a 4:1 male:female ratio.24,48 However, the sex vulnerabil-
ity to ASD appears to change with functioning level; the ratio 
of males to females in children with both ASD and a learn-
ing disability (LD) is 2:1, but it increases to 6–8:1 in ASD 
children who do not have a LD.48 This may itself contribute 
toward an ascertainment bias. For example, a diagnosis of 
ASD may be more frequently considered in LD females 
than in non-LD females.49 Furthermore, sex differences in 
symptom presentation (fewer restricted/repetitive behaviors 
in females) may contribute to differential identification of 
ASD across sexes.49 There is preliminary evidence of abnor-
malities50 and sex-specific differences in the brain structure 
of females with ASD.51,52 Further, there is first evidence of 
possible sex-differences in degree of genetic anomaly associ-
ated with ASD.53 Overall, there is increasing awareness of 
the need to better understand females with ASD54 and how 
their neurobiology, symptoms, and clinical detection may 
differ from those of males.54,55
Autism legislation
Although the importance of providing mental health care for 
adults with ASD is increasingly recognized, to date there is 
relatively little evidence-based research regarding health 
services for adults with ASD and clinical services for adults 
with ASD are markedly limited.5,6 However, government leg-
islation has been introduced internationally to raise awareness 
of autism and fund research. For example, in the USA, 
the Combating Autism Act of 2006/2011 and the subsequent 
Autism Collaboration, Accountability, Research, Education, 
and Support Act of 2014 aim to provide federal funding of 
$3 billion for autism research, services, and training by 2019. 
In Australia, funds of $190 million were released with the 
Helping Children with Autism Package of 2008.
In the UK, legislation was introduced to increase 
awareness of – and mandate services specifically for – adults 
with ASD. The outcome of this legislation is yet to be 
determined. However, the UK legislation is reviewed here 
to illustrate the cross-services working and long-term plan-
ning encountered in efforts to raise awareness and develop 
ASD services. Future comparison of different international 
approaches to raising awareness of ASD, service develop-
ment, and measurement of outcomes may contribute to the 
development of evidence-based care for people with ASD. 
For example, the 2009 Autism Act (the first ever disability-
specific legislation in England) included two important and 
time-specific requirements: that the government produce 
1) an adult ASD strategy by April 2010 and 2) statutory 
guidance (ie, guidance that councils and local health com-
missioning groups are legally required to follow) regarding 
implementation of the strategy by December 2010.
The resulting 2010 UK Adult Autism Strategy provided 
local authorities and national health organizations with mini-
mum requirements regarding how to provide for the needs of 
adults with ASD locally. These included provision of autism 
awareness training for all staff in their employment and also 
specialist autism training for key staff, such as family doctors 
and community workers.
However, considerable geographic variation in service 
provision remained, along with an overall paucity of adult 
ASD services in the UK. As such, the Autism Strategy was 
superseded in 2014 by an updated government strategy, 
Think Autism.56 Think Autism required all 2010 strategy 
recommendations to be upheld and specifically highlighted 
the legal requirement for 1) improved training of frontline 
staff in ASD, 2) development of local ASD teams, 3) better 
planning and commissioning of services with the input of 
people with ASD and their parents/carers, 4) improved access 
to diagnosis and postdiagnostic support, and 5) leadership at 
national, regional, and local levels to help deliver the statu-
tory guidance and determine progress.
The requirements of the Autism Act included service 
development across health and social services. In the UK, 
family doctors (general practitioners [GPs]) are the gatekeep-
ers of access to care for patients. As such, it is important that 
GPs have an awareness of ASD and know how to access 
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clinical and social care for their patients with ASD. In order 
to facilitate this, the UK governing body for family doctors 
(the Royal College of General Practitioners [RCGP]) des-
ignated autism a clinical priority in 2014 and appointed an 
Autism Champion to provide clinical leadership and deliver 
innovative clinical programs.
The outcomes of the RCGP autism initiative are not yet 
available. However, the RCGP plans that it will enable GPs 
to access high-quality training that will lead to delivery of 
the best possible community services, including 1) devel-
opment of ASD friendly services with appropriate referral, 
2) timely diagnosis, 3) appropriate support for people with 
ASD (and their families), and 4) improved health and well-
being outcomes.
Furthermore, adult community mental health teams and 
regional councils are setting up local adult autism services 
to be compliant with Think Autism. Efforts are being made 
to raise awareness among allied professionals of the needs 
of adults with ASD and their families, including social 
workers.57 Hence, while much remains to be done, com-
munity health and social resources for adults with ASD are 
evolving in the UK. Although it is too soon to determine 
the impact of Think Autism, it is hoped that joint working 
across local primary care, community mental health teams, 
hospitals, and local authorities will enable greater awareness 
of ASD and timely provision of high-quality evidence-based 
local services for all adults with ASD. However, there is an 
urgent need for research to determine the impact of ASD 
legislation on people with ASD and their families.7
Diagnosis
why is clarity of diagnosis important in  
ASD?
Although ASD is a common neurodevelopmental disorder, 
at the moment clear biomarkers are not yet available, and so 
ASD is defined and diagnosed on the basis of behavior.58,59 
The diagnosis of ASD has been revised over the last 35 years, 
and early brain imaging as well as genetic and behavioral 
investigations of ASD have contributed to significant 
advances in our understanding of ASD. However, the results 
of some early studies were contrasting, which may have been 
contributed to, in part, by the inclusion of people with unclear 
diagnoses of ASD.59,60
Hence, standardized assessment measures of ASD were 
developed that enabled behavioral observations of the indi-
vidual and collection of collateral developmental history 
from a parent or carer to be quantified and used in addition 
to diagnostic classification systems.59 As ASD is diagnosed 
behaviorally at present, clarity of assessment and diagnosis 
is important to better understand associations between brain, 
behavior, and health in people with ASD across the lifespan 
and enable inclusion of accurately categorized participants 
in large multisite studies.59,61 Better understanding of brain, 
behavior, and diagnosis in people with ASD will, in turn, 
lead to future development of age-appropriate and targeted 
treatments58 and thus improved services for people with ASD. 
As such, the next section will review changes in diagnostic 
practice in ASD.
Diagnosis of ASD
Both an increased awareness of ASD and changes to diagnos-
tic classifications may have partly contributed to the increased 
prevalence of ASD.62 Autistic disturbances of affective 
contact12 and autistic psychopathy63 were first described in 
the 1940s and later translated from German to English by 
Frith.64 However, autism was not included as a diagnostic 
category until the publication of the Diagnostic and Statisti-
cal Manual of Mental Disorders, Third Edition (DSM-III) 
in 1980.65 Additional diagnostic refinements included the 
addition of pervasive developmental disorder not otherwise 
specified (PDD-NOS) in 1987 and inclusion of Asperger’s 
syndrome in DSM-IV.66
The DSM diagnosis of ASD was further revised with the 
recent publication of DSM-5. ASD phenotype diagnoses of 
autistic disorder, Asperger’s syndrome, atypical autism, and 
PDD-NOS were replaced with one diagnosis, namely, ASD. 
Additionally, the three ASD domains included in DSM-IV 
and International Classification of Diseases, Tenth Edition 
(ICD-10) (social reciprocity, communication, and restricted 
and repetitive behaviors) were collapsed into two domains: 
1) social communication/interaction and 2) restricted and 
repetitive behaviors, with evidence required of persistent 
symptoms that cause functional impairment (currently or his-
torically) in these two domains. Furthermore, abnormalities 
in sensory reactivity were added to the restricted/repetitive 
behavior domain. Importantly, DSM-5 acknowledges that, 
although symptoms must begin in early childhood, they 
may become more recognizable in later life with increasing 
social demands. The latter may be particularly relevant for 
individuals whose symptoms may present a different pattern 
or become more obvious with the complexities of adult life 
(eg, females54 or young people transitioning from a structured 
school environment to the less-structured environment of 
college).67
The diagnoses of childhood autism, Asperger’s syn-
drome, atypical autism, and PDD-unspecified are still 
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recognized in the ICD-10 (Table 1), although ICD-11 
(expected publication date 2017) may include revisions to 
this classification system.
The impact of changes to the diagnostic criteria for 
people with ASD is yet to be established.68 However, a 
recent study investigating ASD diagnoses made in adulthood 
compared DSM-5 ASD criteria with ICD-10R and DSM-IV; 
while the specificity of DSM-5 ASD criteria was good, the 
sensitivity was relatively poor.69 For example, 44% of adults 
who received an ASD diagnosis according to ICD-10R did 
Table 1 iCD-10 and DSM-5 diagnostic criteria for ASD
ICD-10 autism (F84.0) DSM-5 ASD
Abnormal or impaired development is evident at the age 
of 3 years in at least one of the following areas:
Although symptoms must begin in early childhood, they may not be 
recognized fully until social demands exceed capacity
1. Receptive or expressive language as used in social communication
2. The development of selective social attachments or of reciprocal 
social interaction
3. Functional or symbolic play
A total of at least six symptoms from (1), (2), and (3) must be 
present, with at least two from (1) and at least one from each 
of (2) and (3):
(1) Qualitative abnormalities in reciprocal social interaction are manifest 
in at least two of the following areas:
1. Social communication/interaction domain: all of the 
following symptoms must be met:
(a) Failure adequately to use eye-to-eye gaze, facial expression, 
body posture, and gesture to regulate social interaction
Problems reciprocating social or emotional interaction, including 
difficulty in establishing or maintaining back-and-forth conversations and 
interactions, inability to initiate an interaction, and problems with shared 
attention or sharing of emotions and interests with others
(b) Failure to develop (in a manner appropriate to mental age, 
and despite ample opportunities) peer relationships that involve 
a mutual sharing of interests, activities, and emotions
Severe problems in maintaining relationships – ranges from lack of 
interest in other people to difficulties in pretend play and engaging in 
age-appropriate social activities and problems adjusting to different 
social expectations
(c) Lack of socioemotional reciprocity as shown by an impaired 
or deviant response to other people’s emotions; lack of modulation  
of behavior according to social context; or a weak integration of 
social, emotional, and communicative behaviors
Nonverbal communication problems, such as abnormal eye contact, 
posture, facial expressions, tone of voice and gestures, and an inability to 
understand these
(d) Lack of spontaneous seeking to share enjoyment, interests, or 
achievements with other people (eg, a lack of showing, bringing, 
or pointing out to other people objects of interest to the individual)
(2) Qualitative abnormalities in communication are manifest in at least 
one of the following areas:
(a) A delaya in, or total lack of, the development of spoken language 
that is not accompanied by an attempt to compensate through the 
use of gesture or mime as an alternative mode of communication 
(often preceded by a lack of communicative babbling)
(b) Relative failure to initiate or sustain conversational interchange 
(at whatever level of language skills is present), in which there is 
reciprocal responsiveness to the communications of the other person
(c) Stereotyped and repetitive use of language or idiosyncratic 
use of words or phrases
(d) Lack of varied spontaneous make-believe or (when young) social 
imitative play
(3) Restricted, repetitive, and stereotyped patterns of behavior, 
interests, and activities are manifest in at least one of the following 
areas:
2. Restricted and repetitive behavior domain: two of the four 
symptoms related to restricted and repetitive behavior must 
be present
(a) An encompassing preoccupation with one or more stereotyped 
and restricted patterns of interest that are abnormal in content 
or focus; or one or more interests that are abnormal in their 
intensity and circumscribed nature though not in their content 
or focus
Stereotyped or repetitive speech, motor movements or use of objects
(b) Apparently compulsive adherence to specific, nonfunctional 
routines or rituals
excessive adherence to routines, ritualized patters of verbal or 
nonverbal behavior, or excessive resistance to change
(Continued)
Neuropsychiatric Disease and Treatment 2016:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1674
Murphy et al
not meet DSM-5 criteria for ASD. Likewise, 22% of adults 
who met DSM-IV-TR diagnostic criteria for Asperger’s or 
autistic disorder did not meet DSM-5 diagnostic criteria for 
ASD. It is unclear how individuals whose symptoms (and 
functional impairment) fall within the broader spectrum of 
ASD according to ICD-10 and DSM-IV, but who no longer 
meet diagnostic criteria for ASD according to DSM-5, will 
be identified and cared for in the future.
Although behavioral diagnostic criteria may fluctuate, 
it is also important to consider potential neurobiological 
factors underlying symptoms and traits of ASD and their 
developmental consequences. For example, language delay 
may serve as a potential marker of atypical brain develop-
ment and behavior, which is of both clinical and research 
utility and may conceivably enable the development of 
individualized treatment.70–72 According to current European 
diagnostic criteria,73 people with autism and Asperger’s both 
meet symptom criteria across the three ASD domains, but 
people with Asperger’s do not have a history of language or 
cognitive delay. The behavioral phenotype is underpinned by 
biological differences in brain in both gray matter volume71,72 
and white matter structure.70 Hence, the particular timing of 
language acquisition may be a possible marker of specific 
developmental changes in brain that may be atypical in some 
people with ASD.70,71 Overall, the debate about the phenom-
enological boundaries of autism continues. However, the 
outcome of this may have significant implications for trans-
lational research, novel treatment trials, personalized thera-
peutic options, and evidence-based service development.
Health
Physical health
Physical health and ASD
There is limited investigation of the physical health of adults 
with ASD. However, a recent retrospective review of health 
records (1,507 adults with ASD and 15,070 adults without 
ASD) found that adults with ASD had significantly increased 
rates of both mental (depression, anxiety, bipolar affective 
Table 1 (Continued)
ICD-10 autism (F84.0) DSM-5 ASD
(c) Stereotyped and repetitive motor mannerisms that involve 
either hand or finger flapping or twisting or complex whole-body 
movements
Highly restricted interests that are abnormal in intensity or focus
(d) Preoccupations with part-objects or nonfunctional elements of 
play materials (such as their odor, the feel of their surface, or the 
noise or vibration that they generate)
Hyper-or hyporeactivity to sensory input or unusual interest in sensory 
aspects of the environment
The clinical picture is not attributable to the other varieties 
of pervasive developmental disorder: specific developmental 
disorder of receptive language (F80.2) with secondary 
socioemotional problems, reactive attachment disorder 
(F94.1) or disinhibited attachment disorder (F94.2), mental 
retardation (F70–F72) with some associated emotional or 
behavioral disorder, schizophrenia (F20) of unusually early 
onset, and Rett’s syndrome (F84.2)
Other ASD diagnoses identified in ICD-10, but not in DSM-5
F84.5 Asperger’s syndrome
Asperger’s syndrome is characterized by the same criteria and the type of qualitative abnormalities of reciprocal social interaction and restricted, 
stereotyped, repetitive repertoire of interests and activities that typify autism. However, Asperger’s differs from autism primarily in that there is no 
general delay or retardation in language or in cognitive development
F84.1 Atypical autism
A type of pervasive developmental disorder that differs from childhood autism either in the age of onset or in failing to fulfill all three sets of 
diagnostic criteria. This subcategory should be used when there is abnormal and impaired development that is present only at the age of 3 years 
and a lack of sufficient demonstrable abnormalities in one or two of the three areas of psychopathology required for the diagnosis of autism (namely, 
reciprocal social interactions, communication, and restricted, stereotyped, repetitive behavior) in spite of characteristic abnormalities in the other 
areas. Atypical autism arises most often in profoundly retarded individuals and in individuals with a severe specific developmental disorder of 
receptive language
F84.9 Pervasive developmental disorder, unspecified
This is a residual diagnostic category that should be used for disorders, which fit the general description for pervasive developmental disorders but in 
which a lack of adequate information, or contradictory findings, means that the criteria for any of the other F84 codes cannot be met
Notes: aFor example, not speaking single words by age 2 years and not speaking communicative phrases by age 3 years. Data from iCD-10178 and DSM-5.179
Abbreviations: ASD, autism spectrum disorder; DSM-5, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; ICD-10, International Classification of Diseases, 
Tenth edition.
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disorder, obsessive–compulsive disorder [OCD], psychosis, 
and self-harm) and physical (sleep, immune and gastrointes-
tinal [GI] disorders, obesity, hyperlipidemia, hypertension, 
seizures, cerebrovascular accidents, and Parkinson’s dis-
ease) health problems.74 Similarly, higher rates of seizures, 
hypertension, and allergies have been reported in smaller 
samples of adults with ASD, along with lower rates of sexu-
ally transmitted diseases, smoking, and alcohol misuse.75 
Importantly, adults with ASD were also found to have the 
same risks of developing some common – and treatable – 
health conditions as the general population: hypothyroidism, 
hyperlipidemia, constipation, and urinary incontinence. 
Furthermore, high rates of poor health have been identified 
among young adults with ASD (34% obesity, 31% hyper-
lipidemia, and 19% hypertension), thereby placing them at 
increased risk of developing diabetes, heart disease, and 
cancer in later life.76
Despite having common and treatable health conditions, 
adults with ASD report difficulty in accessing health care.77 
Crucially, physicians report a lack of awareness of ASD, 
particularly those providing care for adults.78 Overall, the 
findings underline the importance of providing readily acces-
sible evidence-based, age-appropriate primary and hospital 
health care for adults with ASD. This may be facilitated by 
a twofold approach: raising awareness in health profession-
als about ASD in adults and their susceptibility to increased 
rates of some mental and physical health disorders79 but 
also encouraging health professionals to look beyond the 
diagnosis of ASD and to consider the everyday health needs 
of adults with ASD as they would for people who do not 
have ASD.
Overall, there is a dearth of research regarding the 
physical health of adults with ASD. As such, we review three 
health problems reported by children and adults with ASD, 
but using available (pediatric) literature: sleep, GI problems, 
and epilepsy. It is hoped that this may generate both future 
health research and development of health services for adults 
with ASD.
Sleep
Sleep problems are commonly reported in children with ASD 
and typically include difficulties with sleep onset, settling, 
and night waking.80,81 There has been little investigation 
of sleep in adults with ASD, although there is preliminary 
evidence of subjective insomnia82,83 and polysomnograph 
findings of increased sleep latency and night wakings in 
ASD adults.84 It has been suggested that abnormalities in 
melatonin production and circadian timing may contribute 
to insomnia and circadian sleep disturbances in people with 
ASD.81 However, other health variables (medication, obesity, 
epilepsy, GI problems,80 mood, and anxiety83) may also con-
tribute to poor sleep in people with ASD.80
The Autism Treatment Network (ATN) and the National 
Initiative for Children’s Healthcare Quality have developed 
an expert clinical consensus pathway regarding the assess-
ment and management of insomnia in young people (but not 
adults) with ASD.85 This includes recommendations that all 
young people with ASD should be screened for insomnia and 
possible associated factors and, if treatment is indicated, it 
should include parent training, consideration of medication, 
and follow-up to determine efficacy. There is preliminary 
evidence that melatonin can be effective in treating insomnia 
in ASD children,86 but sleep assessment and treatment trials 
in ASD adults are warranted. Overall, although sleep should 
be included in health reviews of people with ASD, greater 
understanding of the causes, treatment, and age trajectories 
of poor sleep are required.80,81
Gi
GI problems are one of the most commonly reported health 
concerns for children with ASD, although prevalence rates 
and treatment options are poorly understood.87 High rates of 
GI and other health problems have been recently reported in 
adults with ASD.74 However, there is little specific investiga-
tion of GI disorders in ASD adults. A recent meta-analysis 
found that, in comparison with non-ASD children, ASD 
children have a threefold elevated risk of GI complaints, 
constipation, and diarrhea and a twofold elevated risk of 
abdominal pain.88 The ATN has released guidelines regarding 
management of constipation in young people with ASD.89
Furthermore, feeding and eating problems are five times 
more common in ASD children and may contribute to GI 
difficulties.90 For example, food selectivity (eating a highly 
limited range of food or just one food) may be associated 
with poor nutrition, altered gut motility, and constipation in 
people with ASD.90,91 Recently published nutritional guide-
lines for the management of GI symptoms in ASD children 
advise that poor nutrition may be contributed to by restricted 
dietary choices (restriction or elimination diets) imposed 
by carers.91 Although data are limited, a small randomized, 
double-blind, crossover study of 15 children (2–16 years 
old) with ASD on gluten- and casein-free diets found no 
significant change in ASD symptoms.92 However, despite 
any absence of evidence supporting their efficacy, children 
with developmental disorders are more likely to be placed 
on restricted or elimination diets by their carers.91,93
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Additionally, social communication difficulties (and asso-
ciated health problems, such as anxiety) may make reporting 
of physical symptoms difficult for some people with ASD. 
Hence, clinicians should consider whether changes in, or 
exacerbations of, behavior such as altered sleep patterns, 
irritability, anxiety, or self-injury may be indicative of physi-
cal problems.88 Consensus recommendations from an expert 
panel of gastroenterologists emphasize the need for increased 
research and evidence-based clinical care.87 However, they 
also contain the important proviso that clinicians should expect 
to see at least the same rate of GI problems in people with 
ASD as they see in people who do not have ASD and should 
provide appropriate assessment and treatment accordingly.
epilepsy
Many studies report that people with ASD have an increased 
risk of epilepsy, although rates vary widely from 2% to 
46%.94 This variability may be due in part to methodological 
differences, including study inclusion criteria and rigor of 
diagnosis of both ASD and epilepsy.94,95 However, a recent 
review identifies female sex and learning disabilities as risk 
factors for epilepsy in people with ASD.94 To date, no seizure 
types are particularly associated with ASD, and there are 
no treatment reviews available regarding the treatment of 
seizures in people with ASD. However, there are concerns 
regarding both under and overdiagnosis of epilepsy in people 
with ASD.94,96 As such, it is recommended that people with 
ASD and possible seizures are referred to neurologists for 
review, that electroencephalograms (EEGs) are performed 
only if there is clinical concern about seizures,94 and that 
sleep96 and metabolic disorders97 are considered in the assess-
ment and management of seizures in people with ASD.
Mental health
Mental health and ASD
Although the mental health needs of adults with ASD are less 
well characterized than those of children with ASD, there is 
evidence that adults with ASD have significantly increased 
rates of mental health problems, including mood and anxiety 
disorders,6,98,99 OCD,100 attention-deficit hyperactivity disor-
der (ADHD),101 and psychotic disorders. Furthermore, these 
comorbid mental health difficulties persist from childhood 
to adulthood102 and occur in both males and females with 
ASD.54,103 Moreover, people with ASD can have specific 
cognitive anomalies, including poor planning, decision 
making, timing, and motor skills,104–107 which may adversely 
impact on their everyday living skills108 and ability to access 
health services.
ADHD in people with ASD
Difficulties with attention are common in people with ASD, 
including problems with switching attention and sustained 
(focused) attention.109–111 It has been suggested that attention 
problems are part of the cognitive phenotype of ASD112 and 
have significant implications for the diagnosis and management 
of ASD and associated mental health difficulties.113 According 
to DSM-IV and ICD-10 guidelines, an individual with ASD 
cannot also be diagnosed with ADHD. However, there is 
increasing recognition that ADHD is common in people 
with ASD106 and persists from childhood to adulthood,102 and 
DSM-5 does allow for the diagnosis of both ASD and ADHD in 
one person. Furthermore, adults with ASD are aware of having 
difficulties with attention and appropriately rate their ADHD 
symptoms using the Barkley ADHD questionnaire.101
There is preliminary evidence that children with ASD 
and comorbid ADHD can benefit from treatment of ADHD, 
including stimulant medication,114 atomoxetine,115 and psy-
chological management.116 However, some young people 
with ASD may respond poorly to medication for ADHD117 
or have increased side effects.116 For example, in a random-
ized control trial of methylphenidate in children with ASD 
and ADHD,117 49% had a therapeutic response (compared 
with a 69% response rate in children with ADHD in the 
Multimodal Treatment Study of Children with ADHD 
(MTA) study.118 Furthermore, 18% of children with ASD 
discontinued medication because of side effects, including 
irritability, loss of appetite, emotional outbursts, and poor 
sleep (compared to 1.4% of children with ADHD in the 
MTA study).
The Autism Speaks ATN Psychopharmacology Com-
mittee has provided a clinical pathway for the assessment 
and management of ADHD in children and adolescents with 
ASD.119 Because of the limited available evidence to date, 
these are primarily based on expert clinical consensus but 
provide guidance on evaluation of symptoms of ADHD in 
children with ASD and, where indicated, choice of medica-
tion. The ATN pathway recommends evaluation of both 
ASD and ADHD using validated assessments, gathering 
collateral history across settings (family/school) where 
available, and consideration of behavioral, environmental, 
and medical factors (including GI, seizures, and anxiety) that 
may be contributing to poor attention. If ADHD is confirmed, 
short-acting methylphenidate is recommended as the first-
line pharmacological treatment of ADHD in young people 
with ASD, with careful clinician monitoring for efficacy and 
possible side effects and exclusion of any cardiac problems 
prior to the initiation of stimulants.119
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To the best of our knowledge, no published evidence 
is yet available regarding pharmacological or psychologi-
cal treatment of ADHD in adults with ASD. As such, best 
practice guidelines (recommendations for clinicians about 
the care of patients with specific conditions, based upon the 
best available research evidence and practice experience) 
should apply (Table 2), including liason of primary care and 
community physicians with psychiatrists and psychologists 
experienced in prescribing and providing psychological 
management for adults with ASD and ADHD.
Furthermore, there is a debate regarding whether people 
with ASD, ADHD, or combined ASD and ADHD have 
shared or different neurobiology. This is important, as an 
increased understanding of the causal mechanisms underly-
ing specific symptoms may contribute to future development 
of individually tailored treatments. For example, recent novel 
functional magnetic resonance imaging (fMRI) studies have 
found both shared and disorder-specific brain differences in 
youth with ASD and ADHD across fMRI tasks of sustained 
attention120 and reward-related temporal discounting.121 Fur-
ther studies are warranted to better understand the neurobiol-
ogy of ASD and common comorbidities, which may enable 
the development of more personalized treatments.
Mood disorders, anxiety, and OCD in people with 
ASD
Affective disorders, including depression,99 anxiety,98 and 
OCD,100 are common in adults with ASD (across both sexes).54 
For example, high rates of depression and anxiety were identi-
fied in adults with Asperger’s syndrome in Sweden; of the 26 
men and 28 women studied, 70% had at least one episode of 
major depression, 50% had recurrent depressive episodes, and 
50% had anxiety disorders, although psychosis and substance 
use were uncommon.99 More recently, a retrospective review 
of clinical assessments of 474 adults with ASD found that 
58% had at least one other psychiatric diagnosis (typically 
anxiety disorders, OCD, depression, and ADHD).103
Despite high rates of anxiety in ASD adults, including 
generalized anxiety, social anxiety, phobias, and OCD,100,122 
anxiety is often overlooked and assumed to be part of an ASD 
profile, rather than warranting a separate diagnosis, which 
can limit access to treatment. However, there is evidence 
that assessment instruments validated for the assessment of 
OCD have direct clinical utility in the assessment of OCD 
in adults with ASD. For example, 40 male and female adults 
with high-functioning ASD and 45 sex-matched adults with 
OCD completed the Yale–Brown Obsessive–Compulsive 
Scale (Y-BOCS) symptom checklist; 25% of the ASD adults 
met Yale–Brown Obsessive–Compulsive Scale and ICD-10 
diagnostic criteria for OCD.100 Additionally, the type of OCD 
symptoms differed across diagnoses; adults with ASD + OCD 
reported more sexual obsessions than OCD adults, who 
reported more somatic obsessions. Recent evidence suggests 
that adults with ASD + OCD engage in significantly more 
checking, ordering, and obsessive behaviors than people 
with ASD without OCD and also order and hoard more than 
people with OCD.123 Additionally, self-report measures of 
OCD (Obsessive–Compulsive Inventory-Revised) appear to 
be useful in screening adults with ASD123 and so may be a 
valuable and cost-effective triage tool for adult ASD mental 
health services.
OCD is, by definition, intrusive, distressing, and 
time-consuming to the individual and their family. OCD 
is ranked by the World Health Organization as a top 20 
cause of years lived with disability;124 barriers to care that 
contribute to this ranking include lack of knowledge and 
poor access to treatment. However, there is evidence that 
psychological treatments adapted for people with ASD can 
provide effective treatment of OCD and anxiety in adults with 
ASD125 and, crucially, that treatment gains are maintained.31 
Hence, although repetitive behaviors are characteristic of 
ASD, it is important not to presume that adults with ASD 
cannot also have OCD or other comorbid (and treatable) 
difficulties. Failure to accurately diagnose symptomatology 
that is present may lead to inadequate treatment and increased 
morbidity.
In summary, adults with ASD commonly experience 
comorbid mental health difficulties.98 However, to date, 
access to ASD diagnostic and management services to enable 
identification and treatment of these disabling conditions is 
extremely limited.5 There is an urgent need for increased 
Table 2 Maudsley Hospital National Autism Service recom-
mendations for good prescribing practice in adults with ASD
1. Start medication at low doses
2. Gradually titrate to maximal efficacy with regular monitoring for side 
effects and individual response to medication targets (eg, use of mood, 
ADHD, and OCD rating scales)
3. Health monitoring before the initiation of, and during the use of, 
medication as appropriate (eg, cardiac review if patient/family cardiac 
history before methylphenidate initiation and lipid/weight monitoring 
with antipsychotics)
4. Stop any aversive or ineffective medication
5. Discuss medication/seek an expert second opinion as indicated
6. Avoid polypharmacy
7. Schedule planned reviews, including whether to continue or stop the 
medication
Abbreviations: ADHD, attention-deficit hyperactivity disorder; ASD, autism 
spectrum disorder; OCD, obsessive–compulsive disorder.
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awareness of ASD, assessment of associated health difficul-
ties, clinical treatment trials, and development of evidence-
based health care for males and females with ASD across 
the adult lifespan.
Service development
Recommendations for assessment of ASD
In the UK, the National Institute for Health and Care 
Excellence (NICE) provides evidence-based guidelines 
(available online) regarding the assessment and management 
of a variety of physical and mental conditions, including the 
care of adults with ASD.126 Although developed for the UK, 
these first recommendations can be adapted for international 
use and provide a benchmark of appropriate care for newly 
developing adult ASD services.
For example, NICE recommends that adults referred for 
assessment of ASD should have a comprehensive, multidis-
ciplinary assessment by trained professionals, which includes 
diagnosis (assessment of core ASD difficulties, early devel-
opment, medical and family history, behavior, education, and 
employment), needs assessment, risks, and feedback to the 
individual. Where possible, a collateral neurodevelopmental 
history should be obtained from parents/carers who have 
known the individual well since early childhood.
If resources allow, NICE recommends the use of validated 
assessment tools to contribute structure and validity to diag-
nostic assessments, such as the Autism Diagnostic Interview-
Revised (ADI-R),127 the Autism Diagnostic Observation 
Schedule-Generic (ADOS),128 the Diagnostic Interview 
for Social and Communication Disorders, the Asperger’s 
Syndrome (and high-functioning autism) Diagnostic 
Interview, and the Ritvo Autism Asperger Diagnostic Scale-
Revised. The ADI-R and ADOS significantly contributed 
to the scientific investigation of ASD by providing robust, 
reliable, and validated ASD assessment criteria, have been 
adopted as gold standard ASD assessment tools,61,129 and 
are also specifically recommended for assessment of ASD 
in people with LD. ASD screening questionnaires avail-
able for use with adults include the Social Responsiveness 
Scale130,131 and the Autism Quotient (AQ),132 although a 
recent comparison of the AQ with expert clinical diagnostic 
consensus (ICD-10, ADI-R and ADOS) found the AQ had 
limited specificity.133 Similarly, screening questionnaires for 
other common mental health comorbidities (eg, the Barkley 
measure of ADHD or the Obsessive–Compulsive Inventory-
Revised) can contribute to the provision of comprehensive 
health services for adults with ASD, including both initial 
assessment and monitoring of response to treatment.
The NICE guidelines also include a range of recom-
mendations for adult service provisions, including care plan-
ning, risk assessment (to self and from others), challenging 
behavior, health passports, crisis plans, second opinions, and 
meeting social and educational needs.
As with any condition where multiple etiologies and/or 
comorbid difficulties are possible, an adequate assessment of 
ASD should include a full medical history, physical exami-
nation, and consideration of known genetic associations 
with ASD, such as 22q11.2 deletion syndrome,134 fragile 
X syndrome, and tuberous sclerosis. Additional medical 
investigations and liason with appropriate physicians are 
recommended where appropriate (Table 3).
However, the behavioral assessment of ASD can be 
time-consuming and expensive and, in the absence of 
biomarkers, relies on expert clinical assessment that is not 
always available.6 As such, tools to improve accuracy, speed, 
cost, and availability of assessment of ASD are important. 
Innovative brain magnetic resonance imaging (MRI) 
diagnostic classification analysis has provided preliminary 
evidence that neuroimaging may aid the behavioral diagnosis 
of ASD.135 For example, Ecker et al demonstrated that adults 
with ASD may be distinguished from typically developing 
adults using neuroanatomical brain scans at an overall 
Table 3 Maudsley Hospital National Autism Service recommendations for medical investigations for adults with ASD
1. Genetic investigation: history of dysmorphic features, congenital anomalies, associated physical health problems (eg, cardiac, metabolic, skeletal, 
and immune), learning difficulties, or family medical history
2. Metabolic investigation: history consistent with anxiety or mood disorder or cramps/leg pains (eg, thyroid and calcium levels)
3. Hematological: history consistent with anxiety or mood disorder
4. Blood monitoring (eg, monitoring of health with psychotropic medication and lipids and drug levels of prescribed medication)
5. Cardiac: eg, eCG/cardiac review prior to starting medication if personal or family cardiac history prior to starting stimulants for ADHD, blood pressure 
monitoring for people prescribed stimulant medication for ADHD, and echocardiography for all people diagnosed with 22q11.2 deletion syndrome134
6. Neurological: eg, eeG for possible epilepsy, brain MRi if indicated
7. Renal: renal ultrasound for all people diagnosed with 22q11.2 DS.134
8. immunology: eg, if recurrent infections
Abbreviations: ADHD, attention-deficit hyperactivity disorder; ASD, autism spectrum disorder; ECG, electrocardiogram; EEG, electroencephalogram; DS, deletion 
syndrome; MRi, magnetic resonance imaging.
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accuracy of 80%–90%. This awaits replication in a clinical 
setting, but it raises the possibility that MRI brain scans may 
contribute to objective, accurate, and time-effective assess-
ment of ASD in the future.
Medication
Despite the increasing prevalence of ASD and associated 
costs,19 no medication is approved for the treatment of 
either core symptoms or comorbid mental health difficul-
ties in adults with ASD.136 Although there is more available 
evidence for psychotropic use in children with ASD than 
adults, overall there is a lack of treatment trials and guidance. 
However, both risperidone and aripiprazole are approved 
by the Food and Drug Administration for the treatment of 
irritability in young people with ASD in the USA. In the UK, 
NICE recommends that medication options for adults with 
autism and associated psychiatric comorbidity are informed 
by existing NICE guidelines for the associated condition 
(eg, ADHD/OCD).
Despite the lack of treatment trials, there is evidence that 
people with ASD are more likely to be prescribed psycho-
tropic medication (primarily sleep medication, stimulants, 
antidepressants, and antipsychotics)137 than the general 
population.138 Furthermore, psychotropic medication is 
increasingly prescribed for young people and adults with 
ASD; in Carolina, 30%–45% of people with ASD are now 
prescribed medication.137 However, prescribing rates do 
vary internationally;139,140 prescribing rates of psychotropics 
for people with ASD in the UK appear more conservative 
(29%), although polypharmacy still occurs.138
Crucially, once people with ASD are prescribed medica-
tion, it is continued. Remarkably, they are eleven times more 
likely than those without ASD to remain on psychotropic 
medication and nearly five times more likely to remain on 
nonpsychotropic medication,137 suggesting either consider-
ably increased rates of health problems requiring medication 
or poor physical and mental health care that lacks medica-
tion review.
It has been suggested that some people with ASD are 
vulnerable to medication side effects, including reduced 
efficacy, toxicity, and idiosyncratic response to medica-
tion (NICE 2012).117,119 The National Autism Service at the 
Maudsley Hospital has been providing specialist in- and 
outpatient clinical mental health services for ASD adults for 
over 20 years. In the absence of any available guidelines, 
Table 2 summarizes the recommended good practice used by 
the authors and colleagues at The Maudsley Hospital, National 
Autism Service, when prescribing for adults with ASD.
Overall, research is urgently needed to increase the under-
standing of response to available medication, develop new 
individualized therapeutic options, identify valid and reliable 
outcome measures, and determine best practice guidelines 
for adults with ASD.141 It is hoped that recent international 
multidisciplinary collaborations will enable the develop-
ment of bench to bedside novel therapeutic options that may 
include consideration of both genetic and neurobiological 
causes of ASD and comorbid difficulties and response to 
treatment. For example, European Autism Interventions - A 
Multicentre Study for Developing New Medications (EU-
AIMS) is a multicenter, European-wide autism initiative to 
develop novel therapeutic options, develop expert clinical 
sites, and provide a shared knowledge platform for people 
with ASD and professionals.142
Psychological management
There are few rigorous studies investigating the effective-
ness of psychosocial interventions143 or cognitive behavioral 
therapy (CBT) in adults with ASD.21 To date, there is one 
randomized control trial31 of modified CBT for treatment of 
OCD/anxiety in adults with ASD (finding good treatment 
response and maintenance over 12 months) and a preliminary 
investigation of mindfulness (finding significant reduction 
in anxiety, depression, and ruminations).144 A randomized, 
controlled open trial of CBT and recreational activity in adults 
with ASD found no significant difference between inter-
ventions in measurements of quality of life, although CBT 
participants rated themselves as more improved in express-
ing needs and understanding difficulties.145 An uncontrolled 
18-month trial of cognitive enhancement therapy (rehabilita-
tion of social and nonsocial cognitions) in 14 adults with ASD 
reported participant satisfaction and significant improvement 
of cognitive and social outcomes.146 Overall, much remains 
to be done to determine the most efficacious evidence-based 
psychological treatments for associated difficulties of adults 
with ASD.31,145
Transition
There is increasing recognition of the need for young people 
with neurodevelopmental disorders to have a planned tran-
sition from child to adult health services (NICE 2012)67,147 
but very limited investigation of how best to do this.148,149 
Differential funding of child and adult services, differing 
eligibility criteria for care and limited awareness among 
physicians78 and other professionals of adult neurodevelop-
mental disorders may contribute to mismatched resources. 
Young adults with ASD may therefore become lost to health 
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care at an important time of increased vulnerability on transi-
tion from adolescent to adult health and education systems. 
Perhaps not surprisingly, many professionals and families 
feel confused about how to navigate the system between 
child and adult services.150
To date, there has been little investigation of the transi-
tion of young people with ASD to adult services. Consen-
sus guidelines regarding transitions for young adults with 
specials care health needs have been available for the last 
decade.151 However, there remains a lack of clear pathways 
providing planned and informed transition between child 
and adult services for people with ASD. Furthermore, 
successful transition requires adaptive skills that can be 
learned and adapted for use across future transitions. For 
example, in addition to moving from child to adult services, 
transitions occur naturally across many life events: adult 
relationships, parenthood, employment, death of a parent/
carer. There is increasing recognition from both people 
with ASD7 and professionals149 of the need for transition 
services to also consider lifelong functioning and adaptive 
skills. Despite this, young people with ASD are 64% less 
likely than other youth with special health care needs to 
receive transition services to adult care.148 Furthermore, 
there is preliminary evidence that access to transition ser-
vices for young people with ASD can be more problematic 
for those from ethnic minorities, with behavioral difficulties 
or anxious parents.152
Older adults
Little is known of the mental and physical health of older 
adults with ASD.10,153 However, an increasing number of 
older adults are being diagnosed with ASD, and future 
research should include the determination of mental and 
physical health in older adults with ASD, including demen-
tia, development of age-appropriate treatment options, and 
consideration of social and financial factors. For example, 
the death of a parent, partner, or older sibling who has been 
caring for an older adult with ASD may adversely impact on 
their mental health and ability to live independently.
There is first evidence of increased rates of Parkinsonism 
in adults (49 years old) with ASD.154 Following neuro-
logical examination and use of the Movement Disorder 
Society-Unified Parkinson’s Disease Rating Scale, ~20% of 
adults with ASD were found to have Parkinsonism (includ-
ing rigidity of tone, bradykinesia, resting tremor, and pos-
tural instability).154 Although the findings are preliminary, 
if confirmed, they have significant implications both for 
understanding the neurobiology of ASD and the development 
of age-specific health services for adults with ASD. Further-
more, there is preliminary evidence of an increased risk of 
early onset age-related disease in genetically determined 
neurodevelopmental disorders that are associated with ASD, 
for example, early onset Alzheimer’s in Down syndrome155 
and preliminary evidence of early onset Parkinson disease 
in 22q11.2 deletion syndrome.156,157 Further research is war-
ranted to investigate the health of older adults with ASD10 
and to determine possible genetic vulnerability toward age-
related disease.
Brain development across the lifespan 
in ASD
ASD is a lifelong neurodevelopmental disorder. Brain imag-
ing studies offer the opportunity for greater understanding 
of brain development and associated behavioral difficulties 
across the lifespan of people with ASD, which may con-
tribute to the development of age-appropriate treatments.158 
For example, there is accumulating longitudinal evidence 
of abnormal, age-related changes in the brain anatomy of 
individuals with ASD in comparison to typically develop-
ing individuals, particularly in frontotemporal and striatal 
regions in early childhood159–161 and adolescence.162 Fur-
thermore, there is increasing cross-sectional evidence of 
region-specific and age-related changes in the brain structure 
of people with ASD from childhood to adulthood across a 
number of areas associated with ASD symptoms, includ-
ing parameters of volume (cerebellum,3 amygdala,163 and 
striatum164) and surface-based measures of cortical thick-
ness and surface area (medial frontotemporal165 and parietal 
regions166). Earlier brain imaging investigations in people 
with ASD suggested that macrocephaly (head circumfer-
ence 97th centile for age and sex) may be a risk factor in 
the development of ASD.167 However, more recent investiga-
tions in larger samples have questioned this168 and suggested 
that true brain overgrowth occurs only in a small subgroup 
of ASD children.158,169
To date, there is a limited fMRI investigation of func-
tional brain maturation in people with ASD. However, there 
is fMRI evidence that sustained attention brain networks 
in people with ASD are activated abnormally and, further-
more, that this is associated with abnormal functional brain 
maturation of fronto-striatal-cerebellar attention networks 
between late childhood and adulthood in people with 
ASD.170 Abnormal activation and maturation of attention 
networks may contribute to attention difficulties across 
the lifespan101,102 and the associated costs of ASD, such as 
loss of earnings/employment or education.19 However, to 
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date, there is limited longitudinal investigation of brain 
maturation in people with ASD from childhood through 
adulthood.
Future developmental investigations are warranted to 
enable better understanding of brain, cognition, and behavior 
in people with ASD across the lifespan, identify biomark-
ers, and develop effective age-appropriate, personalized 
treatments.
Neurochemistry
There is evidence that ASD adults have differences in brain 
chemistry, which may contribute both to ASD symptoms and 
differential response to treatment. Three neurotransmitter 
systems have been a focus of current investigation: gamma 
aminobutyric acid (GABA), glutamine, and serotonin. 
In brief, GABA plays a central role in both neurodevelop-
ment and inhibitory neurotransmission and binds differ-
entially in adults with ASD.171 Conversely, glutamatergic 
(excitatory) neurotransmission appears to be enhanced,9 
while serotonin anomalies have been associated with the 
recognition of emotion and response inhibition in adults 
with ASD.172,173
Crucially, serotonin levels may be modifiable and so 
may offer opportunities for future treatment development. 
For example, an fMRI investigation of the neural processing 
of facial emotions found that modulation of serotonin levels 
normalized the brain activation patterns of ASD adults in 
social brain regions (including frontal lobe, lingual gyrus, 
and limbic areas) to that of typically developing controls.173 
Similarly, fMRI studies of serotonin modulation in tasks of 
impulsivity and inhibition found normalization of brain acti-
vation of ASD adults in key brain inhibition regions (frontal, 
striatal, and cerebellar).172 Positron emission tomography 
studies have reported abnormalities in both serotonin and 
dopamine transporter binding in adults with ASD.174
In addition to its better known hormonal role in facilitat-
ing uterine contractions and milk let down, oxytocin also 
acts as a neuromodulator and is thought to be implicated in 
social cognition. Although results of early oxytocin trials 
are mixed,175 there is preliminary evidence that intransal 
doses of oxytocin are associated with improved empathy 
and reduced repetitive behaviors in adults with ASD.176 
Furthermore, a 12-week modified maximum tolerated dose 
study of oxytocin in 15 young people with ASD found that 
daily administration of oxytocin was well tolerated, with no 
reported serious adverse events, and was associated with 
some changes in measures of social cognition, repetitive 
behavior, and anxiety.177
Overall, translational work is urgently required to bet-
ter understand the potential relationship between brain 
chemistry and behavior in people with ASD and to facilitate 
the development of safe new treatments for adults with ASD.
Conclusion
There has been a considerable increase in ASD research over 
the last 20 years but much remains to be done in health ser-
vices research for people with ASD. In particular, research is 
required to determine a better understanding of the needs of 
adults with ASD, including health, aging, service development, 
transition, treatment options across the lifespan, sex differ-
ences, and the views of people with ASD. Significant legisla-
tive efforts have been put in place internationally to increase 
community and professional awareness of ASD in adults and 
to develop community diagnostic and management services 
for adults with ASD. However, the outcomes of this legisla-
tion remain to be determined. Further research is required to 
identify evidence-based and cost-effective models of care 
and to enable adults with ASD to easily access coordinated, 
high-quality local health and social care. Additionally, future 
work is warranted at both ends of adulthood in ASD: improved 
transition from youth to adult health care and increased under-
standing of aging and health in older adults with ASD.
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